Ocular cuts staff in wake of FDA slapdown; Biogen recruits Pfizer vet; X4 inks discovery deal with Yale
→ Just days after its bid to salvage its second application for the drug/device eye therapy Dextenza failed with another slapdown by regulators, the Ocular Therapeutics $OCUL is cutting staff and shaking up the C suite. The biotech said that Antony Mattessich has assumed the role of CEO while former CEO Amar Sawhney has transitioned to executive chairman. The biotech also reduced its head count by 19%.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.